focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksC4XD.L Share News (C4XD)

  • There is currently no data for C4XD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Thu, 24th Oct 2019 10:31

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 100 - WINNERS

----------

RELX, up 3.4%. The business publisher and analytics firm reaffirmed 2019 guidance after a solid first nine months of the year. RELX delivered 4% underlying revenue growth for the first nine months of 2019, with all four business areas delivering an improvement year-on-year. "The full-year outlook is unchanged. As we enter the final quarter of 2019 key business trends are in line with the full year 2018. We remain confident that, by continuing to execute on our strategy, we will deliver another year of underlying growth in revenue and in adjusted operating profit, together with growth in adjusted earnings per share on a constant currency basis in 2019," said RELX.

----------

AstraZeneca, up 3.2%. The pharma giant posted a dip in third-quarter profit as a result of research & development expenses, but did upgrade annual sales guidance. For the three months ended September, pretax profit was USD409 million, down 14%. This reduction was the result of a 32% rise in selling, general & administrative costs, on top of a 5.5% jump in research & development expense. Total revenue rose 20%, reaching USD6.41 billion thanks both to a 16% rise in product sales and to a more than trebling of collaboration revenue. Astra has upgraded product sales guidance for 2019 and is now expecting a low to mid-teens percentage rise, having previously expected a low double-digit percentage increase. Astra also reiterated guidance for core earnings per share of between USD3.50 and USD3.70 for 2019 as a whole.

----------

AVEVA Group, up 2.2%. The engineering and industrial software firm said strong sales execution has led to solid revenue growth. AVEVA achieved low double-digit revenue growth on a proforma constant-currency basis in the financial first half ended September. On a reported basis, revenue benefited from foreign exchange movements, the company said. The revenue mix was "positive", said AVEVA, with every region delivering growth. Rental & Subscription was "very strong", partly offset by expected lower revenue in the Initial & Perpetual Licences and Services units.

----------

FTSE 100 - LOSERS

----------

Royal Bank of Scotland, down 2.2%. In the three months to September 30, RBS recorded an operating pretax loss of GBP8 million compared to a GBP961 million profit a year before. The loss was attributed to a GBP900 million PPI provision. The bank's loss attributable to shareholders totalled GBP315 million, compared to a GBP448 million profit in the third quarter last year and a GBP1.33 billion profit in the second quarter of this year. Net interest income declined 6.5% to GBP2.01 billion from GBP2.15 billion. RBS said its group was hurt from a "particularly challenging" quarter from investment bank NatWest Markets.

----------

FTSE 250 - WINNERS

----------

KAZ Minerals, up 6.2%. The miner expects to beat gold guidance for 2019 after a "record" third quarter of the year. KAZ has previously guided for 2019 gold production between 170,000 ounces and 185,000 ounces. However, it now expects to beat the top end of that range by 5%. This comes after third-quarter gold production of 58,500 ounces for the three months to September, 32% higher than the quarter before. Copper production was 82,900 tonnes, 6.8% higher than the prior three months. KAZ said the rises in production came after strong performances from the Aktogay mine in eastern Kazakhstan and the Bozshakol mine in the north of the country.

----------

FTSE 250 - LOSERS

----------

RHI Magnesita, down 4.4%. The refractory products firm warned a continued deterioration in steel-sector sales volumes are hurting earnings. As a result, RHI Magnesita is predicting 2019 adjusted earnings before interest, tax, and amortisation to be between EUR400 million and EUR410 million, down from the EUR428.1 million recorded in 2018. The Vienna, Austria-headquartered company said Steel revenue for the three months to September 30 has fallen 14% year-on-year and a materially lower contribution from the Steel unit in the second half against the first half is now expected. The global steel market has weakened further and, as a result, customers have significantly reduced their refractory products inventories, RHI Magnesita explained.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Woodford Patient Capital Trust, up 30%. The firm has appointed Schroder Investment Management as its new portfolio manager, following the exit of star fund manager Neil Woodford last week. Schroder Investment Management, part of FTSE 100 listed asset manager Schroders, will take over as portfolio manager by the end of 2019, when the trust will be renamed Schroder UK Public Private Trust.

----------

Petro Matad, up 76%. The Mongolian oil explorer reported positive results from testing of the Heron-1 well. A first test was performed over a three metre zone at 2,872 metres and indicated an oil column height of at least 70 metres in the Heron-1 well. The second drill stem test was performed over a 12 metre interval from 2,834 metres, with oil and some associated gas flowing to surface without the need for any artificial lift. The peak production recorded during the test was 821 barrels of oil per day and, for the main flow period, the well flowed at an average rate of 200 barrels a day. The company said the Heron-1 flow rate was very encouraging and could indicate a "too conservative" recovery estimate for the Heron structure, however more wells would be required to prove the total volumes in the structure.

----------

Motif Bio, up 23%. The biopharmaceutical firm is to team up with a US Army-funded research institute to evaluate the use of iclaprim in administering antibiotics.

----------

Eurasia Mining, up 32%. The firm said two of the largest investment banks in Russia and China have expressed interest in the company's assets, with talks over their future ongoing.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

C4X Discovery, down 57%. The firm is to raise GBP5.5 million by placing shares at 15 pence each, and also offer 1 share per 9 existing in an open offer to raise a further GBP1.0 million. C4X will use the funds to strengthen the balance sheet and expands the portfolio.

----------

Mobile Streams, down 31%. The firm continues to seek a new nominated advisor, but will not make the October 28 deadline when shares will be suspended if it has not done so. After that, it has a month to get a new nomad, or it will be removed from the London Stock Exchange.

----------

Distil, down 20%. The alcoholic drinks maker swung to a loss in the first half with the company citing tough conditions in the UK unflavoured gin market. The company, which owns the RedLeg rum brand, Blackwood's gin and Blavod vodka, swung to a first half pretax loss of GBP1,000 in the six months to September 30. Last year, it made a GBP101,000 pretax profit. Revenue fell by 29% year-on-year to GBP824,000 from GBP1.2 million. For the full-year Distil expects revenue to lag behind market forecasts, though the company expects operating profit to be in line due to cost control measures.

----------

By George Collard; georgecollard@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
28 Nov 2022 10:46

AIM WINNERS & LOSERS: C4X shares jump on agreement with AstraZeneca

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
28 Nov 2022 08:49

C4X Discovery shares up as signs USD400 million deal with AstraZeneca

(Alliance News) - C4X Discovery Holdings PLC on Monday said it signed an exclusive worldwide licensing agreement with AstraZeneca PLC for its NRF2 Activator programme.

Read more
20 Oct 2022 21:54

TRADING UPDATES: XPS Pensions revenue up; IG Design performing ahead

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Aug 2022 15:39

C4X raises £5.7m to support development activities

(Sharecast News) - Drug discovery company C4X announced a proposed placing to raise up to £5.7m on Thursday, to support its corporate development and ongoing commercial activities.

Read more
11 Aug 2022 13:17

UPDATE: C4X Discovery raises GBP5.7 million in oversubscribed placing

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Raises total of GBP5.7 million from placing 22.8 million shares with institutional investors at 25 pence each. Notes placing shares represents about 9.9% of existing shares.

Read more
11 Aug 2022 11:17

AIM WINNERS & LOSERS: MJ Hudson falls short of fundraising target

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
11 Aug 2022 10:49

IN BRIEF: C4X plans GBP5.7 million placing to aid drug development

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Proposes placing to raise up to GBP5.7 million through issue of EIS/VCT shares and general placing shares at 25 pence each.

Read more
2 Aug 2022 18:01

IN BRIEF: C4X Discovery sees momentum across drug discovery portfolio

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Says it has made continued progression across its drug discovery portfolio. Says it is in advanced stage commercial discussions for its NRF2 activator programme for inflammatory diseases with a deal anticipated in the second half of 2022. Also says its MALT-1 inhibitor programme for haematological and solid tumours has compounds, that match the leading clinical candidate in terms of in vitro and in vivo profile, is now moving towards identifying a "best-in-class shortlist of compounds".

Read more
6 Jul 2022 19:33

IN BRIEF: C4X Discovery receives milestone payment from Sanofi deal

C4X Discovery Holdings PLC - Manchester-based developer of drug discoveries - Receives milestone payment of EUR3 million from French pharma firm Sanofi SA under the IL-17A inhibitor programme licence agreement, first signed in April 2021.

Read more
28 Apr 2022 19:25

TRADING UPDATES: Impellam's first quarter beats pre-virus levels

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
21 Apr 2022 16:10

UK earnings, trading statements calendar - next 7 days

Friday 22 April 
Alphawave IP Group PLCFull Year Results
Petropavlovsk PLCTrading Statement
Record PLCTrading Statement
Serabi Gold PLCFull Year Results
Zinc Media Group PLCFull Year Results
Monday 25 April 
Access Intelligence PLCFull Year Results
Arecor Therapeutics PLCFull Year Results
Audioboom Group PLCFull Year Results
CentralNic Group PLCTrading Statement
Chapel Down Group PLCFull Year Results
Lok'n Store Group PLCHalf Year Results
Vector Capital PLCFull Year Results
Tuesday 26 April 
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Billington Holdings PLCFull Year Results
Corero Network Security PLCFull Year Results
Focusrite PLCHalf Year Results
Futura Medical PLCFull Year Results
Gaming Realms PLCFull Year Results
Hochschild Mining PLCTrading Statement
HSBC Holdings PLCQ1 Results (at 0500 BST)
Immotion Group PLCFull Year Results
IWG PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Learning Technologies Group PLCFull Year Results
Loungers PLCTrading Statement
National Express Group PLCTrading Statement
Northcoders Group PLCFull Year Results
Nostrum Oil & Gas PLCFull Year Results
PureTech Health PLCFull Year Results
RWS Holdings PLCHalf Year Results
Taylor Wimpey PLCFull Year Results
Wednesday 27 April 
1Spatial PLCFull Year Results
AB Dynamics PLCHalf Year Results
Anglo Pacific Group PLCQ1 Results
Aveva Group PLCTrading Statement
City Pub Group PLCFull Year Results
Drax Group PLCTrading Statement
Fresnillo PLCQ1 Production Results
GlaxoSmithKline PLCQ1 Results
Go-Ahead Group PLCHalf Year Results
Lloyds Banking Group PLCQ1 Results
London Stock Exchange Group PLCTrading Statement
Network International Holdings PLCTrading Statement
Nichols PLCFull Year Results
Persimmon PLCTrading Statement
Primary Health Properties PLCTrading Statement
RPS Group PLCQ1 Results
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Yamana Gold IncTrading Statement
Thursday 28 April 
Angle PLCFull Year Results
Barclays PLCQ1 Results
Brave Bison Group PLCFull Year Results
C4X Discovery Holdings PLCHalf Year Results
Evraz PLCQ1 Results
Flutter Entertainment PLCQ1 Results
Glencore PLCTrading Statement
Howden Joinery Group PLCTrading Statement
HSS Hire Group PLCFull Year Results
Hurricane Energy PLCFull Year Results
Inchcape PLCTrading Statement
Indivior PLCQ1 Results
International Personal Finance PLCTrading Statement
J Sainsbury PLCFull Year Results
Keystone Law Group PLCFull Year Results
Lancashire Holdings LtdQ1 Trading Statement
Novacyt SAFull Year Results
PPHE Hotel Group LtdTrading Statement
Sanderson Design Group PLCFull Year Results
Schroders PLCTrading Statement
Smith & Nephew PLCQ1 Results
Spectris PLCQ1 Results
St James's Place PLCTrading Statement
Standard Chartered PLCQ1 Results
Unilever PLCQ1 Results
Whitbread PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
11 Jan 2022 14:59

CORRECT: UK shareholder meetings calendar - next 7 days

CORRECT: UK shareholder meetings calendar - next 7 days

Read more
11 Jan 2022 14:46

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
21 Dec 2021 12:57

C4X Discovery appoints Cathy Tralau-Stewart as new science chief

(Sharecast News) - Drug discovery company C4X announced the appointment of Catherine Tralau-Stewart as its new chief scientific officer on Tuesday, effective from 4 January.

Read more
13 Dec 2021 17:52

TRADING UPDATES: Tristel, K3 Capital, MyHealthChecked expect growth

TRADING UPDATES: Tristel, K3 Capital, MyHealthChecked expect growth

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.